Helicobacter pylori Eradication Treatments and Risk of Alzheimer Disease: A Case-Control Study Nested in the Finnish Population
- PMID: 39868701
- PMCID: PMC11957437
- DOI: 10.1097/EDE.0000000000001831
Helicobacter pylori Eradication Treatments and Risk of Alzheimer Disease: A Case-Control Study Nested in the Finnish Population
Abstract
Background: Helicobacter pylori ( H. pylori ) has been inconsistently associated with the risk of Alzheimer disease. The exposure assessment period has often overlapped with the prodromal time of Alzheimer disease. Cognitive disorders might increase vulnerability to infectious pathogens, complicating the ascertainment of the temporal relationship between H. pylori infection and Alzheimer disease.
Methods: This Finnish nested case-control study included 70,520 persons with incident Alzheimer disease diagnosed between 2005 and 2011 and 281,233 age-, sex-, and region of residence-matched controls. We obtained information on comorbidities and drug use from the national healthcare registers. We identified dispensed H. pylori eradication treatments from the Prescription Register. We considered exposure at least 5 years before Alzheimer disease diagnosis in the main analysis. We compared the risk of Alzheimer disease between H. pylori eradication treatment users and nonusers using confounder-adjusted (comorbidities and other drug use) conditional logistic regression. We assessed cumulative exposure by calculating the number of eradication treatments.
Results: The prevalence of exposure to H. pylori eradication treatment at least 5 years before the outcome was 4.1% in cases and 3.9% in controls. The odds ratio (95% confidence interval) was 1.06 (1.02, 1.11) in the crude and 1.03 (0.99, 1.07) in the confounder-adjusted model. We observed no association between cumulative exposure and risk of Alzheimer disease.
Conclusion: Our results, reflecting diagnosed and treated H. pylori infection late in life, do not support the hypothesis of H. pylori as an independent risk factor for Alzheimer disease. The previously reported association may be explained by reverse association and confounding.
Keywords: Alzheimer disease; Case–control study; Confounding factors; Epidemiologic; Risk factors.
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
Disclosure: A.-M.T. reports research grant from Amgen, paid through the institution she is employed, outside of the submitted work. The other authors have no conflicts of interest.
Similar articles
-
Analysis of Patients with Helicobacter pylori Infection and the Subsequent Risk of Developing Osteoporosis after Eradication Therapy: A Nationwide Population-Based Cohort Study.PLoS One. 2016 Sep 14;11(9):e0162645. doi: 10.1371/journal.pone.0162645. eCollection 2016. PLoS One. 2016. PMID: 27626940 Free PMC article.
-
Helicobacter pylori eradication therapy is not associated with the onset of inflammatory bowel diseases. A case-control study.J Gastrointestin Liver Dis. 2018 Jun;27(2):119-125. doi: 10.15403/jgld.2014.1121.272.hpy. J Gastrointestin Liver Dis. 2018. PMID: 29922755
-
Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.Korean J Intern Med. 2015 Nov;30(6):801-7. doi: 10.3904/kjim.2015.30.6.801. Epub 2015 Oct 30. Korean J Intern Med. 2015. PMID: 26552455 Free PMC article.
-
N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication.Cochrane Database Syst Rev. 2019 Feb 12;2(2):CD012357. doi: 10.1002/14651858.CD012357.pub2. Cochrane Database Syst Rev. 2019. PMID: 30746681 Free PMC article.
-
Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis.Gastroenterology. 2021 Nov;161(5):1443-1459. doi: 10.1053/j.gastro.2021.07.043. Epub 2021 Aug 3. Gastroenterology. 2021. PMID: 34358488 Free PMC article.
References
-
- Alzheimer's Association. 2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 2023;19:1598–1695. - PubMed
-
- Piekut T, Hurła M, Banaszek N, et al. . Infectious agents and Alzheimer’s disease. J Integr Neurosci. 2022;21:73. - PubMed
-
- Zamani M, Ebrahimtabar F, Zamani V, et al. . Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868–876. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical